MASLD, MLA Pesarattu and Other Developments.
作者信息
Anand Anil C
机构信息
Department of Gastroenterology & Hepatology, Kalinga Institute of Medical Sciences, Bhubneshwar, India.
出版信息
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102465. doi: 10.1016/j.jceh.2024.102465. Epub 2024 Nov 22.
Abstract
摘要
相似文献
1
MASLD, MLA Pesarattu and Other Developments.
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102465. doi: 10.1016/j.jceh.2024.102465. Epub 2024 Nov 22.
2
Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Health Sci Rep. 2025 Jun 18;8(6):e70920. doi: 10.1002/hsr2.70920. eCollection 2025 Jun.
3
The Rising Global Burden of MASLD and Other Metabolic Diseases (2000-2021).
United European Gastroenterol J. 2025 Sep;13(7):1141-1154. doi: 10.1002/ueg2.70072. Epub 2025 Jul 3.
4
The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort.
Front Endocrinol (Lausanne). 2025 Jun 4;16:1619003. doi: 10.3389/fendo.2025.1619003. eCollection 2025.
5
Comparable Long-Term Liver Transplant Outcomes in Primary Sclerosing Cholangitis with and without MASLD: Last Decade Analysis of the UNOS Database.
Dig Dis. 2025;43(5):569-581. doi: 10.1159/000547227. Epub 2025 Jul 4.
6
Dietary lipophilic index and odds of metabolic dysfunction-associated steatotic liver disease (MASLD): A population-based study.
Dig Liver Dis. 2025 Jul;57(7):1455-1464. doi: 10.1016/j.dld.2025.04.001. Epub 2025 May 13.
7
Associations between high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and their ratio with metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.
Front Endocrinol (Lausanne). 2025 Jun 18;16:1585811. doi: 10.3389/fendo.2025.1585811. eCollection 2025.
8
Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers.
Acta Diabetol. 2025 Jun 24. doi: 10.1007/s00592-025-02536-w.
9
Identification of Preclinical Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) versus MASLD and Increased Alcohol Intake and the Impact of Diet.
Am J Pathol. 2025 Jun 12. doi: 10.1016/j.ajpath.2025.05.013.
10
Serum Tsukushi level is negatively associated with cholesterol efflux capacity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Sci Rep. 2025 Jul 1;15(1):21883. doi: 10.1038/s41598-025-06431-w.
本文引用的文献
1
Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What's in the Name?
Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):1-4. doi: 10.5005/jp-journals-10018-1424.
2
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):218-228. doi: 10.1016/S2468-1253(23)00443-0. Epub 2024 Jan 11.
3
Definition of Metabolic Dysfunction: Shifting Goalposts.
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101301. doi: 10.1016/j.jceh.2023.11.001. Epub 2023 Nov 7.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
5
Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate.
World J Hepatol. 2023 Feb 27;15(2):123-128. doi: 10.4254/wjh.v15.i2.123.
6
NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.
Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S1-S4. doi: 10.5005/jp-journals-10018-1363.
7
MAFLD: How is it different from NAFLD?
Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29.
8
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?
Ann Hepatol. 2022 Nov-Dec;27(6):100765. doi: 10.1016/j.aohep.2022.100765. Epub 2022 Sep 28.
9
Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.
J Clin Exp Hepatol. 2022 May-Jun;12(3):818-829. doi: 10.1016/j.jceh.2021.11.010. Epub 2021 Nov 25.
10
Lean Fatty Liver Disease: Through Thick and Thin.
J Clin Exp Hepatol. 2021 Sep-Oct;11(5):523-527. doi: 10.1016/j.jceh.2021.06.011. Epub 2021 Jun 18.
Zotero 插件